

A Retrospective Cohort Study to Assess Drug Utilisation and Long-Term Safety of Galcanezumab in European Patients in the Course of Routine Clinical Care (I5Q-MC-B002)

First published: 17/01/2019

Last updated: 28/10/2024

Study

Ongoing

Administrative details

PURI

<https://redirect.ema.europa.eu/resource/36549>

EU PAS number

EUPAS27594

Study ID

36549

DARWIN EU® study

No

Study countries

- ☐ France
 - ☐ Germany
 - ☐ Italy
 - ☐ Netherlands
 - ☐ Spain
 - ☐ Sweden
 - ☐ United Kingdom
-

Study description

To evaluate the utilisation and long-term safety of galcanezumab in Europe, in routine clinical practice.

Study status

Ongoing

Research institutions and networks

Institutions

The PHARMO Institute for Drug Outcomes Research (PHARMO Institute)

- ☐ Netherlands

First published: 07/01/2022

Last updated: 24/07/2024

Institution

Laboratory/Research/Testing facility

ENCePP partner

Leibniz Institute for Prevention Research and Epidemiology - BIPS

☐ Germany

First published: 29/03/2010

Last updated: 26/02/2024

Institution

Not-for-profit

ENCePP partner

The PHARMO Institute for Drug Outcomes Research (PHARMO Institute)

☐ Netherlands

First published: 07/01/2022

Last updated: 24/07/2024

Institution

Laboratory/Research/Testing facility

ENCePP partner

Quantify Research

☐ Sweden

First published: 09/07/2020

Last updated: 14/02/2023

Institution

Other

ENCePP partner

Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, IDIAPJGol

☐ Spain

First published: 05/10/2012

Last updated: 23/02/2024

Institution

Educational Institution

Laboratory/Research/Testing facility

Not-for-profit

ENCePP partner

Bordeaux PharmacoEpi, University of Bordeaux

☐ France

First published: 07/02/2023

Last updated: 08/02/2023

Institution

Educational Institution

Hospital/Clinic/Other health care facility

Not-for-profit

ENCePP partner

Agenzia regionale di sanità della Toscana (ARS)

☐ Italy

First published: 01/02/2024

Last updated: 12/03/2024

University of Basel, in collaboration with the
Boston Collaborative Drug Surveillance Program
United Kingdom, University Institute for Primary
Care Research Jordi Gol and University of Oxford
Spain, Agenzia regionale di sanita della Toscana
Italy, Quantify Research Sweden

Contact details

Study institution contact

Enemona Adaji

Study contact

enemona.emmanueladaji@lilly.com

Primary lead investigator

Eline Houben

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 17/01/2019

Actual: 18/01/2019

Study start date

Planned: 30/06/2020

Actual: 30/06/2020

Date of final study report

Planned: 31/12/2026

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

Eli Lilly and Company

Study protocol

[I5Q-MC-B002 Galcanezumab_EU Long Term Safety_Drug Utilization_Protocol_amendment_Redacted.pdf](#)(3.6 MB)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Drug utilisation

Main study objective:

To evaluate the utilisation and long-term safety of galcanezumab in Europe, in routine clinical practice.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Study drug International non-proprietary name (INN) or common name

GALCANEZUMAB

Medical condition to be studied

Migraine

Cluster headache

Population studied

Age groups

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Estimated number of subjects

100

Study design details

Outcomes

Cardiovascular, malignancy, and serious hypersensitivity.

Data analysis plan

Descriptive analysis

Data management

Data sources

Data source(s)

Clinical Practice Research Datalink

The Information System for Research in Primary Care (SIDIAP)

PHARMO Data Network

German Pharmacoepidemiological Research Database

ARS Toscana

Data source(s), other

CPRD, SIDIAP, PHARMO Data Network, GePaRD, ARS

Data sources (types)

[Administrative healthcare records \(e.g., claims\)](#)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No